Kurma Partners to Collaborate with Samsung Biologics for the Development and Manufacture of Biologics Drugs
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics and European venture capital firm Kurma Partners have announced that they are set to enter into a collaboration.
The strategic partnership will see Samsung Biologics develop and manufacture drugs for Kurma’s portfolio companies, including by providing chemistry, manufacturing, and control (CMC) development.
This development will entail streamlining the journey from gene identification to filing for an investigational new drug (IND). Furthermore, it is hoped that this will hasten the pipeline from lead candidate selection to clinical testing of new drugs.
RELATED:
- Toward Sustainable Packaging Solutions for Drug Manufacturers
- Navigating the Drug Development Pipeline from Discovery to Product
- Sustainable Drug Formulation: Paving the Path for Greener Pharmaceutical Future
Samsung Biologics is an end-to-end CDMO which offers solutions from cell line development to final aseptic fill and finish as well as laboratory testing support. In the agreement, Kurma gets access to Samsung Biologics’ facilities, technology platform and knowledge of CMC development. John Rim, President and CEO of Samsung Biologics, said:
"With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients."
Kurma Partners is based in Paris and Munich and finances a wide selection of healthcare and biotech companies with the funds that they provide to the life sciences industry. Daniel Parera, Partner at Kurma Partners, said: "We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market."
